TLR4 and ovarian carcinoma: In ovarian cancer, Paclitaxel’s interaction with TLR4 on TAMs activates NF-κB, shifting macrophages toward an M1 profile marked by increased production of pro-inflammatory cytokines such as TNFα and IL12.